Format
Sort by

Send to

Choose Destination

Search results

Items: 19

1.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
2.

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Wellcome Trust Case Control Consortium, Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.

3.

Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS).

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.

PMID:
22467927
4.

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; Wellcome Trust Case Control Consortium; British Society for Rheumatology Biologics Register, Barton A.

Arthritis Rheum. 2011 Mar;63(3):645-53. doi: 10.1002/art.30130.

5.

Calcinosis in juvenile dermatomyositis.

Tugnet N, Rees DH.

Postgrad Med J. 2010 Aug;86(1018):510. doi: 10.1136/pgmj.2010.101170. No abstract available.

PMID:
20709775
6.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

7.

Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.

Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS.

Pharmacogenet Genomics. 2009 Apr;19(4):319-23. doi: 10.1097/FPC.0b013e328328d51f.

PMID:
19262425
8.

Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.

Maxwell JR, Potter C, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Hum Mol Genet. 2008 Nov 15;17(22):3532-8. doi: 10.1093/hmg/ddn245. Epub 2008 Aug 19.

9.

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A; BRAGGSS.

Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ard.2007.084715. Epub 2008 Mar 28. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

10.

Increased IgA rheumatoid factor and V(H)1 associated cross reactive idiotype expression in patients with Lyme arthritis and neuroborreliosis.

Axford JS, Rees DH, Mageed RA, Wordsworth P, Alavi A, Steere AC.

Ann Rheum Dis. 1999 Dec;58(12):757-61.

11.

The value of serological testing for Lyme disease in the UK.

Rees DH, O'Connell S, Brown MM, Robertson J, Axford JS.

Br J Rheumatol. 1995 Feb;34(2):132-6.

PMID:
7704458
12.

Lyme arthritis.

Rees DH, Axford JS.

Ann Rheum Dis. 1994 Sep;53(9):553-6. Review. No abstract available.

13.

Crohn's and sarcoidosis: different manifestations of the same disease process?

Kiely PD, Rees DH, Axford JS.

Br J Clin Pract. 1994 Sep-Oct;48(5):274-5. No abstract available.

PMID:
7917826
14.

Borrelia burgdorferi and localized scleroderma.

Trevisan G, Rees DH, Stinco G.

Clin Dermatol. 1994 Jul-Sep;12(3):475-9. Review. No abstract available.

PMID:
7954205
15.

Lyme disease: a rare but clinically important disease in the UK.

Rees DH, Axford JS.

Equine Vet J. 1994 May;26(3):175-7. No abstract available.

PMID:
8542833
16.
17.

Lyme disease in sub-Saharan Africa.

Adebajo AO, Axford JS, Rees DH.

J Rheumatol. 1994 Mar;21(3):580. No abstract available.

PMID:
7911837
18.
19.

Some designs of use in serology.

Rees DH.

Biometrics. 1967 Dec;23(4):779-91. No abstract available.

PMID:
4965887
Items per page

Supplemental Content

Loading ...
Write to the Help Desk